The historic rise of Viagra has long been a benchmark of pharmaceutical success, however its legacy within the broader market now triggers questions about long-term gains. Copycat versions are diminishing market share, causing worries that investing in companies significantly dependent to Viagra's previous standing could be a dangerous decision , e